Johnson & Johnson

Key Findings

• Economic: Johnson & Johnson maintains substantial Israeli operations, including manufacturing and R&D through Omrix and Biosense Webster, Israeli innovation partnerships, and the 2024 V-Wave acquisition.^{1, 2, 3, 4}
• Political: J&J participates in the FutuRx public-private incubator, established with Israeli government-linked innovation funding; it also donated $2 million in humanitarian relief after the 7 October 2023 attacks while issuing no identified conflict-specific statement on Gaza or Palestinian civilian harm.^{3, 5}
• Settlements: No public evidence identified that J&J operates facilities, sales offices, or service infrastructure in Israeli settlements; it is not listed in the UN settlement-activity database or the Who Profits database.^{6, 7}
• Not found: No verified Israeli military, defence-procurement, surveillance, cloud-government, or digital-security nexus was identified in the audits.^{8, 9, 10}

Target Profile

Key Facts:

• J-C Health Care Ltd. is an active Israeli J&J subsidiary; J&J reports more than 1,000 employees across four Israeli sub-companies.^{17, 18}
• Omrix operates biomanufacturing in Har Hotzvim, West Jerusalem; Biosense Webster operates a Yokneam R&D and manufacturing centre.^{1, 2}
• J&J completed its acquisition of Israeli heart-failure-device company V-Wave in October 2024.⁴

Executive Summary

Johnson & Johnson’s documented Israel nexus is principally economic and institutional rather than military or digital. The company retains Israeli healthcare and MedTech operations through wholly owned subsidiaries and acquired businesses, including Omrix Biopharmaceuticals, Biosense Webster, J-C Health Care/Janssen Israel, and V-Wave. Its Israeli footprint includes manufacturing, medical-device R&D, venture investment, and participation in the FutuRx biotechnology incubator near Weizmann Science Park.^{1, 2, 3, 4}

The strongest documented vector is the company’s continuing contribution to Israel’s civilian life-sciences economy. Omrix manufactures plasma-derived immunoglobulins in West Jerusalem, while Biosense Webster’s Yokneam facility is described as a global technology centre for cardiac electrophysiology and mapping systems. J&J also has Israel-based investment staff and acquired V-Wave for $600 million upfront, with potential milestone payments bringing the transaction total higher.^{1, 2, 4, 15}

The political-domain record is more limited but includes J&J’s FutuRx partnership with the then Office of the Chief Scientist, now Israel Innovation Authority. The audit also records a $2 million humanitarian-relief donation after the 7 October 2023 Hamas attacks and identifies no conflict-specific public statement by J&J addressing Gaza, Palestine, or Palestinian civilian harm.^{3, 5} J&J’s U.S. lobbying and PAC activity is documented, but no Israel-specific lobbying or anti-BDS lobbying was identified in the reviewed filings.¹⁹

The audits do not substantiate military, weapons, defence-procurement, surveillance, Project Nimbus, or Israeli state-cloud involvement. They also identify no direct settlement operation, and record that J&J is absent from several commonly cited settlement, arms, and occupation-focused company databases.^{6, 7, 8, 9, 10} The fixed human-vetted result is therefore driven by the depth, scale, and directness of the documented economic footprint and government-linked innovation relationship, not by a verified military or digital nexus: BRS 603, Tier B (Severe Complicity).

Timeline of Relevant Events

Corporate Overview

Johnson & Johnson is a New Jersey-incorporated, NYSE-listed healthcare corporation. Following the 2023 Kenvue spin-off, its retained businesses are Innovative Medicine and MedTech.^{11, 12} The audits identify no Israeli founding origin, Israeli state equity, golden share, state-appointed director, or corporate-governance mechanism tying J&J’s mission or continuity to the Israeli state.^{11, 13}

Its documented Israeli corporate footprint includes J-C Health Care Ltd. (the Janssen Israel operating entity), Omrix Biopharmaceuticals, Biosense Webster, and other Israeli subsidiaries reflected in SEC materials. J&J also maintains Israeli venture-investment activity through J&J Innovation personnel based in Israel.^{15, 17, 22}

The operational relationship is not limited to sales. Omrix conducts biomanufacturing in Har Hotzvim Technology Park, West Jerusalem, a location the audit identifies as west of the Green Line and not a settlement. Biosense Webster operates R&D and manufacturing in Yokneam, and J&J acquired V-Wave in 2024. J&J’s FutuRx relationship links it to an Israeli life-sciences incubator involving the Israel Innovation Authority’s predecessor, Takeda, and OrbiMed.^{1, 2, 3, 4}

Domain Summaries

Military: Military

Mechanism of Involvement

No verified direct Israeli defence contracting or procurement relationship was identified. The audits found no verified contracts, tenders, framework agreements, or memoranda involving J&J or its subsidiaries and the Israeli Ministry of Defence, IDF, Israel Prison Service, or Border Police. No public evidence identified of J&J appearing as a defence supplier in relevant procurement, export, or exhibition materials.^{8, 9}

Omrix manufactures plasma-derived immunoglobulins, including Vaccinia Immune Globulin, a product category that may have civilian and biodefence applications. However, no public evidence identified of direct IDF, Israeli Ministry of Defence, or weapons-programme procurement of those products.^{1, 8} J&J’s clinical MedTech platforms are documented as civilian systems, not tactical or defence-grade products.⁸

Omrix operated a blood bank at Sheba Medical Center until 2021. The audit notes Sheba’s role as a major military and combat-trauma treatment centre, but identifies no verified logistical or base-services contract and no evidence of support to IDF bases beyond those historical blood-bank operations.²³

Counter-Arguments and Evidence Limits

The strongest defence is that J&J is a civilian pharmaceutical and medical-technology company, not an arms, heavy-machinery, or defence-infrastructure manufacturer. The audits found no verified supply relationship with Elbit, IAI, Rafael, or Israel Military Industries; no weapons-system, munitions, or strategic-platform role; and no Israeli defence export-licensing or enforcement record.^{8, 9}

J&J is also not listed in the UN settlement-business database, PAX’s report on companies arming Israel, or the Who Profits database. Board members’ prior professional backgrounds do not, on the audited evidence, establish a J&J defence-supply relationship.^{6, 7, 10, 16}

Named Entities and Evidence Map

• Omrix Biopharmaceuticals: Israeli J&J subsidiary; civilian biomanufacturing, including products with possible biodefence relevance, without identified Israeli defence procurement.^{1, 8}
• Sheba Medical Center: historical Omrix blood-bank location through 2021; no verified military-service contract identified.²³
• Marillyn A. Hewson / Dr. Nadja West: board members with former Lockheed Martin and U.S. Army leadership roles respectively; no audited evidence connects those roles to J&J Israeli military supply.¹⁶

Digital: Digital

Mechanism of Involvement

No public evidence identified of J&J licensing, deploying, or integrating named Israeli-origin cybersecurity, surveillance, biometrics, predictive-policing, or workforce-monitoring technologies. No public evidence identified of J&J operating data centres in Israel or participating in Project Nimbus or comparable Israeli government cloud programmes.^{9, 10}

J&J MedTech’s Microsoft partnership covers digital surgery using Azure, AI, machine learning, IoT, and edge computing. The audit treats it as a commercial B2B relationship and found no evidence it serves Israeli state customers.²¹ J&J’s clinical robotics portfolio is likewise documented as clinical rather than military or law-enforcement technology.⁹

Counter-Arguments and Evidence Limits

The documented Yokneam facility is an R&D and manufacturing centre for civilian cardiac electrophysiology and mapping technology, not an identified surveillance or security operation.² The audit also notes that Magalcom lists J&J among commercial clients while holding Israeli Ministry of Defence contracts, but does not establish that J&J used Magalcom for defence-related, surveillance, or security work.²⁴

No public evidence identified of military, intelligence, policing, cloud-hosting, analytics, AI, or digital-weapons contracts with Israeli state-security bodies.⁹

Named Entities and Evidence Map

• Biosense Webster: Yokneam R&D/manufacturing operation for clinical cardiac mapping systems.²
• Microsoft: strategic partner for J&J digital surgery; no Israeli-state customer nexus identified.²¹
• Magalcom: commercial-client listing involving J&J; its separate defence contracts do not establish a transitive J&J defence relationship.²⁴

Economic: Economic

Mechanism of Involvement

J&J’s most substantial documented nexus is its civilian healthcare and innovation presence in Israel. J-C Health Care Ltd. is an active Israeli entity serving as Janssen Israel’s operating entity. The audits report more than 1,000 employees across four Israeli sub-companies, alongside commercial, R&D, manufacturing, and investment activities.^{17, 18}

Omrix operates plasma-derived immunoglobulin manufacturing in West Jerusalem, and Biosense Webster operates a Yokneam global R&D and manufacturing technology centre for cardiac electrophysiology and mapping systems. J&J also acquired V-Wave in 2024, further expanding its Israeli MedTech footprint.^{1, 2, 4}

J&J participates in FutuRx, a public-private biotechnology incubator near Weizmann Science Park. The partnership includes the Office of Chief Scientist/Israel Innovation Authority, Takeda, and OrbiMed, and provides funding, advice, and pharmaceutical-development expertise to Israeli life-sciences companies.³

Counter-Arguments and Evidence Limits

The audit found no evidence that J&J is a food retailer, produce importer, or purchaser of Israeli agricultural exports, including settlement-origin agricultural products. Its Israel-related procurement is described as pharmaceutical raw materials, device components, and R&D outputs rather than food or retail goods.¹²

No public evidence identified of a separate Israeli revenue figure, material Israeli sovereign-bond holdings, Israeli state ownership, or material Israeli-domiciled controlling shareholding. Profit flows from wholly owned Israeli subsidiaries are described as upstream to the U.S. parent, while J&J does not publicly disaggregate Israeli revenue from broader international or EMEA reporting.^{13, 17}

The audit corrects a potentially misleading attribution: J&J did not acquire Itamar Medical; ZOLL Medical, an Asahi Kasei subsidiary, acquired it.²⁵

Named Entities and Evidence Map

• J-C Health Care Ltd. / Janssen Israel: active Israeli operating entity based in Shefayim.¹⁷
• Omrix Biopharmaceuticals: J&J-owned Israeli biomanufacturing operation in West Jerusalem.^{1, 20}
• Biosense Webster: Yokneam R&D and manufacturing operation.²
• V-Wave: Israeli structural-heart-device company acquired by J&J in 2024.⁴
• FutuRx / Israel Innovation Authority: public-private life-sciences-incubator relationship involving J&J.³

Political: Political

Mechanism of Involvement

J&J’s political nexus rests principally on its government-linked innovation participation and public posture. The Office of the Chief Scientist, now Israel Innovation Authority, provided approximately $2 million in government funding to establish the FutuRx incubator; J&J is a corporate partner in that ecosystem.^{3, 26}

After the 7 October 2023 Hamas attacks, J&J condemned the attacks, spoke against antisemitism, and made a $2 million humanitarian donation. The audit did not identify a J&J press release specifically naming Gaza or Palestine, nor a named conflict-specific public statement addressing Palestinian civilian harm.⁵

J&J has U.S. lobbying and PAC activity. The audit records approximately $9–11 million annually in U.S. lobbying expenditures from 2020–2023 and PAC contributions across both major parties in the 2023–24 cycle, while identifying no registered Israel-specific, anti-BDS, or U.S.-Israel-trade lobbying activity.¹⁹

Counter-Arguments and Evidence Limits

No public evidence identified of J&J operations in Israeli settlements, nor of formal territorial-operation complaints, OECD National Contact Point complaints, or international rulings targeting J&J. Corporate disclosure does not granularly distinguish every Israeli domestic location from settlement-territory operations, but available audit checks found no identified settlement facility or service infrastructure.^{6, 7}

No public evidence identified of corporate donations to FIDF, JNF/KKL, settlement-linked organizations, or named geopolitical advocacy groups; likewise, no public evidence identified of such affiliations by CEO Joaquin Duato or current executives and board members reviewed.^{5, 14}

Named Entities and Evidence Map

• FutuRx / Office of Chief Scientist / Israel Innovation Authority: government-linked innovation partnership involving J&J.^{3, 26}
• J&J PAC: bipartisan U.S. political-action committee activity; no Israel-specific lobbying identified in the audit.¹⁹
• Joaquin Duato: CEO; no audited evidence of personal Israel-Palestine public statements or relevant named donations.¹⁴

BDS-1000 Score

Method: V6.5.

• V_MAX: 7.00 Avg_OTHERS: 1.17
• BRS Score: 603 Tier: B (Severe Complicity)

V_MAX is driven by the documented scale and directness of J&J’s Israeli manufacturing, R&D, acquisitions, investment activity, and public-private innovation partnership. The political score reflects that government-linked ecosystem and documented public posture, while the military and digital scores remain zero because the audits found no verified qualifying nexus. The V6.5 method is scale-free, evidence-only, and human-vetted; it does not infer responsibility from association alone.

Methodology Note

• Evidence is limited to the four supplied domain audits and their cited documentary record.
• Impact (I) measures the documented activity type; Magnitude (M) measures its scale; Proximity (P) measures the directness of the documented nexus.
• The method is scale-free: scores do not purport to measure total harm, intent, corporate value, or comparative moral worth.
• Divested, exited, or corrected operations are mitigated or excluded; notably, J&J’s non-acquisition of Itamar Medical is treated as a corrected attribution.²⁵
• Entity attribution is direct: a client listing, director biography, shareholder holding, or third party’s separate defence activity does not establish transitive corporate guilt.
• Settlement activity may count in both Economic and Political where documented; “No public evidence identified” is used where the audits’ checks found no qualifying evidence.